Research compounds
Thymopentin
TP-5, Timunox
Thymopentin is a synthetic pentapeptide corresponding to residues 32-36 of thymopoietin, the active fragment of a thymic hormone. It has been used as an immunomodulator in some countries and has been studied in HIV and in rheumatoid arthritis.
Also known as: TP-5, Timunox, thymopoietin pentapeptide
- Status
- Thymopentin is a research compound and not approved by the FDA for human use.
- Evidence
- Early human data. Only small or early-phase studies in people so far.
- Half-life
- Approximately 30 seconds in plasma.
- How it's taken
- Subcutaneous or intramuscular injection in non-clinical use
- Mechanism
- Immune modulation
- Pathways
- Thymic Immune
How Thymopentin works
Thymopentin reproduces the biologically active region of thymopoietin, a thymic peptide involved in T-cell differentiation. It appears to promote maturation of T-cell precursors and to modulate T-cell subset ratios, with effects described on interleukin-2 production and lymphocyte responsiveness. The mechanism is characterised in less detail than the marketing around thymic peptides suggests.
What research has looked at
- It was studied in randomised trials in HIV, rheumatoid arthritis and atopic dermatitis during the 1980s and 1990s, so a genuine clinical literature exists.
- It has been marketed as an immunomodulator in several countries outside the United States.
- Its very short sequence makes synthesis straightforward and well controlled.
Evidence level: Early human data. Only small or early-phase studies in people so far. These are areas studied or reported, not promised effects.
Reported side effects and risks
- It is not approved by the FDA, and the trial literature is old, small and largely inconclusive by modern standards. No regulator has approved it, the human evidence base is limited, and material sold under this name is research chemical supply with unverified identity, purity, sterility and dose accuracy.
- Its plasma half-life is on the order of seconds, which makes any sustained systemic effect from intermittent injection difficult to explain.
- Immunomodulation without a defined target carries theoretical autoimmune risk that has not been characterised over long periods.
- Injection-site reactions and transient flushing were reported in trials.
Sources
- PubMed research on thymopentin TP-5 immunomodulator trials · NIH · National Library of Medicine
- DrugBank record for thymopentin · DrugBank
- Active clinical trials for thymopentin · U.S. National Library of Medicine
Track Thymopentin in Peptide Vault
Log every dose, set reminders on your own schedule, rotate injection sites and keep your vials organized. Peptide Vault records what you enter. It doesn't recommend compounds or doses. iPhone, on-device.
Related compounds
Thymopentin FAQ
What is Thymopentin?
Thymopentin is a synthetic pentapeptide corresponding to residues 32-36 of thymopoietin, the active fragment of a thymic hormone. It has been used as an immunomodulator in some countries and has been studied in HIV and in rheumatoid arthritis.
How does Thymopentin work?
Thymopentin reproduces the biologically active region of thymopoietin, a thymic peptide involved in T-cell differentiation. It appears to promote maturation of T-cell precursors and to modulate T-cell subset ratios, with effects described on interleukin-2 production and lymphocyte responsiveness. The mechanism is characterised in less detail than the marketing around thymic peptides suggests.
Is Thymopentin FDA approved?
No. Thymopentin is a research compound and not approved by the FDA for human use. Evidence level: early human data. Only small or early-phase studies in people so far.
What is the half-life of Thymopentin?
Reported half-life: Approximately 30 seconds in plasma.
How is Thymopentin taken?
Subcutaneous or intramuscular injection in non-clinical use.
What side effects have been reported with Thymopentin?
Reported in the sources: It is not approved by the FDA, and the trial literature is old, small and largely inconclusive by modern standards. No regulator has approved it, the human evidence base is limited, and material sold under this name is research chemical supply with unverified identity, purity, sterility and dose accuracy; Its plasma half-life is on the order of seconds, which makes any sustained systemic effect from intermittent injection difficult to explain; Immunomodulation without a defined target carries theoretical autoimmune risk that has not been characterised over long periods; Injection-site reactions and transient flushing were reported in trials.
Educational summary compiled from the sources listed above. Not medical advice. Peptide Vault does not sell, source or recommend any compound. Talk to a qualified clinician before starting or changing anything.